Abionyx Pharma SA banner

Abionyx Pharma SA
LSE:0RAG

Watchlist Manager
Abionyx Pharma SA Logo
Abionyx Pharma SA
LSE:0RAG
Watchlist
Price: 1.896 EUR -0.73%
Market Cap: €266.8k

Intrinsic Value

0RAG price has not been updated for more than 8 months. This may indicate that the stock has been delisted.

The intrinsic value for Abionyx Pharma SA (0RAG) under the Base Case is 1.257 EUR. Compared with the current market price of 1.896 EUR, the stock appears Overvalued by 34% .

Intrinsic value calculated using Multiples
€1.257
Other reference points

Do our valuations actually work? See backtest results .

0RAG Intrinsic Value
1.257
Overvaluation 34%
Intrinsic Value
Price €1.896
Monitor 0RAG
Get notified when the price drops
Track Buy Zone
20% below Intrinsic Value €1.01
Get notified when the price drops into your buy zone
Current Price €1.9
Intrinsic Value €1.26
Margin of Safety 20% €1.01
Or choose another margin of safety
0% below Intrinsic Value
10% below Intrinsic Value
30% below Intrinsic Value
40% below Intrinsic Value
50% below Intrinsic Value
Custom
Ask AI Assistant
What other research platforms think about 0RAG?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is 0RAG valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Abionyx Pharma SA.

Explain Valuation
Alternatives to 0RAG

Wall St Price Targets

Capital Returns

Competitive Landscape

Ownership

ABNX Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one 0RAG stock?

The intrinsic value for Abionyx Pharma SA (0RAG) under the Base Case is 1.257 EUR.

Is 0RAG stock undervalued or overvalued?

Compared with the current market price of 1.896 EUR, the stock appears Overvalued by 34% .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett